This is a single-center double blind, placebo controlled study of patients undergoing a cardiac catheterization where the need for a percutaneous coronary intervention (PCI) is anticipated or will be determined during the early diagnostic phase. The study will assess the use of intracoronary nicardipine vs. sterile saline injection in reducing the index measurement of microcirculatory resistance (IMR). Fifty consecutive patients presenting to the Thomas Jefferson University (TJUH) Cardiac Catheterization lab will be randomized in a 1:1 fashion to receive either intracoronary nicardipine or sterile saline injection prior to PCI. IMR values will be assessed pre and post procedure. Data on clinical outcomes and adverse events will be collected by phone at 30 days and 1 year following the procedure.

开始日期2025-12-01

申办/合作机构

Thomas Jefferson University

NCT06093893 / Not yet recruiting临床4期IIT

A Comparison of Dexmedetomidine, Nicardipine, and Labetalol to Induce Hypotensive Anesthesia and Their Effects on Surgeon Visibility, Blood Loss, Hemodynamic Parameters, Operation Time, and Adverse Events During Orthognathic Surgery

The overall objective of this double blinded, randomized controlled trial (RCT) is to compare specific outcomes of three medications (Dexmedetomidine, Nicardipine, and Labetalol) which are routinely used to lower blood pressure used during general anesthesia for orthognathic (jaw) surgery. The outcome measures for the study will be surgical field visibility, estimated blood loss, hemodynamic parameters, operation time, and adverse events.
The specific objectives of this study are to compare:
1. Dexmedetomidine, Nicardipine, and Labetalol's effect on the quality of the surgical field. (Primary Outcome)
2. Dexmedetomidine, Nicardipine, and Labetalol's effect on estimated blood loss.
3. Dexmedetomidine, Nicardipine, and Labetalol's effect on hemodynamic parameters including systolic blood pressure, mean arterial pressure, and heart rate.
4. Dexmedetomidine, Nicardipine, and Labetalol's effect on operation time.
5. Dexmedetomidine, Nicardipine, and Labetalol's effect on adverse events.
The investigators will evaluate healthy adult male and female patients who require jaw surgery at Boston Medical Center. The anticipated 90 participants will be randomized into three groups: ) A Labetalol group in which the patients receive hypotensive anesthesia with the aid of labetalol, 2) A Nicardipine group in which the patients receive hypotensive anesthesia with the aid of nicardipine, and 3) A Dexmedetomidine group in which the patients receive hypotensive anesthesia with the aid of dexmedetomidine.
The time it will take for each individual participant ranges from 1-3 months. This time includes the pre-operative visit, the surgical procedure, a 1-week post-operation visit, and then followed for 30 days post-operatively after which the patient's participation in the study will conclude.

开始日期2024-05-01

申办/合作机构

Boston Medical Center

NCT06329635 / Not yet recruitingN/AIIT

Trial of Treatment of Vasospasm Associated With Aneurysmal Subarachnoid Hemorrhage With Intrathecal Injection of Nicardipine: a Multi-center, Prospective, Double-blinded, Randomized Controlled Trial

To investigate whether patients with cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage have a better prognosis with intrathecal nicardipine injection via extraventricular drainage or lumbar drainage.

开始日期2024-04-01

申办/合作机构

贵州医科大学附属医院

100 项与盐酸尼卡地平相关的临床结果

登录后查看更多信息

100 项与盐酸尼卡地平相关的转化医学

登录后查看更多信息

100 项与盐酸尼卡地平相关的专利（医药）

登录后查看更多信息

8,837

项与盐酸尼卡地平相关的文献（医药）

2024-02-29·Heliyon

RSM-based modelling for predicting and optimizing the rheological and mechanical properties of fibre-reinforced laterized self-compacting concrete.

Article

作者: Sharanabasava Patil ; B Ramesh ; T Sathish ; A Saravanan

A sustainable method to reduce the use of natural resources and the negative effects of the concrete industry on the environment is to use waste lateritic aggregate in self-compacting concrete and evaluate its fresh, mechanical and durability characteristics. Using RSM's central composite design (CCD), Thirteen different SCC mixtures have been designed with varying input factor combinations (LA: 0-100%, PPF: 0-2%) and tested for eight responses (rheological properties, like slump flow, V-funnel time, and T500; mechanical properties, like compressive, split-tensile, and flexural strengths, and durability properties like drying shrinkage and rapid chloride penetration test). The analysis of variance (ANOVA) test was performed to determine the accuracy of the mathematical models developed following the experimental results. ANOVA was used to verify eight response models (seven quadratic and one linear). The inclusion of laterite aggregate has been found to linearly reduce the workability of fresh concrete. Self-compacting concrete will have a lower V-funnel value if any combination of components falls below these two limit values (31% LA and 1.12% PPF). The area bounded by the 760-mm contour line and the graph axes recorded the highest slump flow at (28% LA and 1.26% PPF). Similarly, SCC with a lower T500 value will be produced by any combination of components below these two limit values (25% LA and 1.11% PPF). By replacing 28.5% of the granite aggregate with laterite aggregate and adding 1.24% polypropylene fiber, the compressive strength of M30 grade self-compacting concrete increased by 12.33% after 28 days. A similar strength gain of 7.89% was seen in the splitting tensile by replacing 28% of the granite aggregate with laterite aggregate and adding 1.46% polypropylene fiber over the control mix, and a flexural strength gain of 14.46% was seen by replacing 31.4% of laterite aggregate and adding 1.2% polypropylene fiber, respectively. The low drying shrinkage values are related to a combination of LA concentration (34.4% replacement) and PPF (1.31%) and minimum chloride ingress is located in the region with a LA concentration (30.5% replacement) and a PPF content (1.26%), The projected optimal data were verified experimentally with an error rate of less than 5%. Thus, it is highly recommended that the created model be adequate and capable of optimizing both the experimental and analytical values. It is recommended that the utilization of 25% LA and 1% PPF in lateritic self-compacting concrete provides optimum outcomes for the construction industry in the field of civil engineering.

2024-02-22·AIDS research and human retroviruses

"This is actually a really unique moment in time": Navigating Long-Acting HIV Treatment and HIV Cure Research with Analytical Treatment Interruptions - A Qualitative Interview Study in the United States.

Article

作者: Karine Dube ; Amaya Perez-Brumer ; Hursch Patel ; Carina Zhou ; Lynda Dee ; Gail Graham ; Steven Meanley ; Morgan Philbin

Advancements in long-acting (LA) HIV treatment and cure research with analytical treatment interruptions (ATIs) have generated important scientific and implementation questions. There is an urgent need to examine challenges navigating the evolving HIV treatment and cure research landscape. From August - October 2022, we conducted 26 semi-structured interviews with biomedical researchers and community members representing a predominantly woman demographic to explore the complexity of navigating the rapidly evolving HIV therapeutic and HIV cure research landscape. We purposively sampled individuals recruited from the AIDS Clinical Trials Group and the Martin Delaney Collaboratories for HIV Cure Research. Audio files were transcribed verbatim and analyzed via a thematic approach, using an inductive and iterative process. Among 26 participants, 10 were biomedical researchers and 16 community members, including 11 were people with HIV. Three main themes emerged: 1) We are at a pivotal moment in the evolving landscape of HIV therapeutics and LA HIV treatment and HIV cure research should not be siloed but considered together; 2) There are challenges with engagement in HIV cure research and in switching between oral daily antiretroviral treatment and LA formulations and, mainly, the prolonged pharmacokinetic tail of these compounds matched with limited patient education about their impacts; and 3) There are unique opportunities as a result of this evolving therapeutic landscape, including the key role of decision support for people with HIV, centering around patient autonomy, and the need to learn from the lived experiences of people with HIV who choose LA treatment and/or participation in HIV cure research. Despite a bias towards the woman gender, our study identifies key considerations for navigating concurrent LA HIV treatment and HIV cure research with ATIs from both community members and biomedical researchers' perspectives. Achieving optimal HIV control remains a formidable challenge, necessitating robust interdisciplinary collaborations and engagement with key stakeholders.

2024-02-22·Scientific reports

Polyunsaturated fatty acids-induced ferroptosis suppresses pancreatic cancer growth.

Article

作者: Akane Suda ; Banlanjo Abdulaziz Umaru ; Yui Yamamoto ; Hiroki Shima ; Yuriko Saiki ; Yijun Pan ; Liang Jin ; Jiaqi Sun ; Yi Ling Clare Low ; Chitose Suzuki ; Takaaki Abe ; Kazuhiko Igarashi ; Toru Furukawa ; Yuji Owada ; Yoshiteru Kagawa

Despite recent advances in science and medical technology, pancreatic cancer remains associated with high mortality rates due to aggressive growth and no early clinical sign as well as the unique resistance to anti-cancer chemotherapy. Current numerous investigations have suggested that ferroptosis, which is a programed cell death driven by lipid oxidation, is an attractive therapeutic in different tumor types including pancreatic cancer. Here, we first demonstrated that linoleic acid (LA) and α-linolenic acid (αLA) induced cell death with necroptotic morphological change in MIA-Paca2 and Suit 2 cell lines. LA and αLA increased lipid peroxidation and phosphorylation of RIP3 and MLKL in pancreatic cancers, which were negated by ferroptosis inhibitor, ferrostatin-1, restoring back to BSA control levels. Similarly, intraperitoneal administration of LA and αLA suppresses the growth of subcutaneously transplanted Suit-2 cells and ameliorated the decreased survival rate of tumor bearing mice, while co-administration of ferrostatin-1 with LA and αLA negated the anti-cancer effect. We also demonstrated that LA and αLA partially showed ferroptotic effects on the gemcitabine-resistant-PK cells, although its effect was exerted late compared to treatment on normal-PK cells. In addition, the trial to validate the importance of double bonds in PUFAs in ferroptosis revealed that AA and EPA had a marked effect of ferroptosis on pancreatic cancer cells, but DHA showed mild suppression of cancer proliferation. Furthermore, treatment in other tumor cell lines revealed different sensitivity of PUFA-induced ferroptosis; e.g., EPA induced a ferroptotic effect on colorectal adenocarcinoma, but LA or αLA did not. Collectively, these data suggest that PUFAs can have a potential to exert an anti-cancer effect via ferroptosis in both normal and gemcitabine-resistant pancreatic cancer.

项与盐酸尼卡地平相关的新闻（医药）

2024-04-07

·米内网

3月5个首仿、3个1类新药获批，4个品种获批新适应症，这家企业仿制申报最多

摘要abstract2024年3月7个1类新药、5个改良型新药申请上市；167个品种按新分类仿制申请申报，其中33个品种暂无国内仿制获批，石家庄四药申报品种数最多；32个存量品种有企业申报一致性评价，其中2个品种为首次申报。3款1类新药获批上市，4个品种获批新适应症；15个品种首家过评，其中5个为首仿。创新药品种申报情况2024年3月，97个创新药品种（药品注册分类为“1”的品种）获CDE承办。7个品种申请上市：己二酸他雷替尼胶囊(葆元生物医药(杭州))、盐酸来罗西利片(玉溪嘉和生物)、盐酸去甲乌药碱注射液(珠海润都制药)、注射用Datopotamab Deruxtecan(第一三共)、注射用苏维西塔单抗(江苏先声生物)、通络健脑片(广州悦康生物制药)、紫花温肺止嗽颗粒(广州悦康生物制药)。2024年3月创新药上市申请承办情况2024年3月创新药临床申请承办情况改良型新药品种申报情况2024年3月，19个改良型新药品种获CDE承办，5个品种申请上市，呋喹替尼胶囊(和记黄埔医药(上海))、古塞奇尤单抗注射液(强生)、聚乙二醇干扰素α-2b注射液(厦门特宝生物)、赛沃替尼片(和记黄埔医药(上海))为新适应症上市申请。2024年3月改良型新药上市申请承办情况2024年3月改良型新药临床申请承办情况新分类仿制药品种申报情况2024年3月，167个品种仿制申请获CDE承办，33个品种目前暂无国内仿制药获批。石家庄四药共有10个品种获CDE承办：比拉斯汀片、二羟丙茶碱注射液、复方醋酸钠林格注射液、富马酸福莫特罗吸入溶液、精氨酸培哚普利片、氯化钙注射液、吗啉硝唑氯化钠注射液、葡萄糖酸钙注射液、盐酸尼卡地平氯化钠注射液、盐酸左沙丁胺醇雾化吸入溶液。2024年3月新分类仿制药品种申报情况存量品种一致性评价申报情况2024年3月，32个品种的一致性评价补充申请获CDE承办。法罗培南钠片和复合磷酸氢钾注射液为首次申报。2024年3月存量品种一致性评价申报情况获批情况2024年3月有3款1类新药获批上市：秦威颗粒(成都华西天然药物)、妥拉美替尼胶囊(上海科州药物研发)、泽沃基奥仑赛注射液(恺兴生命科技(上海))。4个品种获批新适应症：佩索利单抗注射液(皮下注射)(勃林格殷格翰)、舒格利单抗注射液(辉瑞)、阿布昔替尼片(辉瑞)、阿那白滞素注射液(苏庇医药)。103个品种按新分类仿制申请获批，44个品种按存量品种一致性评价补充申请过评。15个品种首家过评，其中ω-3甘油三酯(2%)中/长链脂肪乳/氨基酸(16)/葡萄糖(16%)注射液(四川科伦药业)、醋酸钙口服溶液(山东朗诺制药)、盐酸阿那格雷胶囊(黑龙江天宏药业)、依折麦布辛伐他汀片(北京福元医药)、注射用塞替派(江苏恒瑞医药)等5个品种为国内首仿。2024年3月主要注册类型品种获批情况数据来源：米内网中国申报进度数据库（MED）、CDE、NMPA；相关统计字段按药品名称统计，时间截至2024年3月31日；获批品种按NMPA发布时间统计；药物作用靶点以及适应症整理自公开资料。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

一致性评价上市批准

2024-04-03

·米内网

【重磅】齐鲁抢首仿，剑指亿级抗帕金森氏病药

精彩内容4月3日，齐鲁制药提交了恩他卡朋双多巴片(II)的4类仿制上市申请。恩他卡朋双多巴是一款畅销抗帕金森氏病药，2022年在中国公立医疗机构终端的销售额超过1亿元。今年以来，齐鲁制药已有4个新产品获批，6个新产品申报上市。图1：齐鲁制药最新申报的产品来源：CDE官网图2：国内市场已上市的恩他卡朋双多巴制剂来源：米内网中国上市药品（MID）数据库恩他卡朋双多巴是卡比多巴、恩他卡朋和左旋多巴的三联复方制剂，适用于治疗经左旋多巴/多巴脱羧酶(DDC)抑制剂疗法未能控制的出现或伴有“剂末”运动功能波动的成人帕金森病患者。米内网数据显示，目前国内市场上已有原研的恩他卡朋双多巴片、恩他卡朋双多巴片(II)、恩他卡朋双多巴片(III)、恩他卡朋双多巴片(IV)上市销售，4个产品均未有国产仿制药获批。图3：恩他卡朋双多巴的销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局恩他卡朋双多巴在2019年进入国家医保目录，随后在中国城市公立医院、县级公立医院、城市社区及乡镇卫生院（简称中国公立医疗机构）终端的销售额飞速增长，2022年突破1亿元。2023年上半年在抗帕金森氏病药市场，恩他卡朋双多巴为TOP6品种。2022年12月，石家庄四药首家提交了恩他卡朋双多巴片(II)的4类仿制上市申请，目前正在审评审批中。本次齐鲁报产，将参与该产品的国内首仿争夺。表1：2024年至今齐鲁制药获批的新产品（按批文日期统计）来源：米内网中国申报进度（MED）数据库今年以来，齐鲁制药及子公司已获批了4款新产品，其中艾曲泊帕乙醇胺片为国内首仿（含同日获批），公司的抢仿实力不容小觑。值得注意的是，今年以来齐鲁制药及子公司已提交了6个新产品的仿制上市申请，包括了西尼莫德片、盐酸尼卡地平注射液、注射用米卡芬净钠、注射用拉氧头孢钠、立他司特滴眼液和恩他卡朋双多巴片(II)，其中西尼莫德片、立他司特滴眼液和恩他卡朋双多巴片(II)暂无国内药企获得生产批文。资料来源：CDE官网、米内网数据库等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至4月3日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准一致性评价

2024-03-25

·信狐药迅

ADC品种临床申请占据同类申请半数以上| 新受理（3.18-3.24）

本周药品注册受理数据，分门别类呈现，一目了然。(3.18-3.24）小编收到有些用户反应，不想收到咱们每周文章的推送提醒，而有些用户又特别需要这个提醒，在小编强烈要求下，我们给力的程序员终于实现了可以关闭提醒的功能，这个绝对全网独一家喔，不想收到提醒的，只要在信狐药迅对话框内回复关键词“拒收文章提醒”，那么就可以不受推送的打扰啦!新药上市申请无新药临床申请药品名称企业注册分类受理号YK-051南京优科制药有限公司1CXHL2400296177Lu-LNC1010注射液烟台蓝纳成生物技术有限公司1CXHL2400286盐酸杰克替尼片苏州泽璟生物制药股份有限公司1CXHL2400298盐酸杰克替尼片苏州泽璟生物制药股份有限公司1CXHL2400297HLX99片上海复宏汉霖生物技术股份有限公司1CXHL2400292HLX99片上海复宏汉霖生物技术股份有限公司1CXHL2400291HLX99片上海复宏汉霖生物制药有限公司1CXHL2400290盐酸希美替尼片中国科学院上海药物研究所1CXHL2400289盐酸希美替尼片中国科学院上海药物研究所1CXHL2400288D-1553片益方生物科技(上海)股份有限公司1CXHL2400287盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHL2400295盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHL2400294盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHL2400293HCB101注射液广州汉科生物有限公司1CXSL2400200注射用BAT8008百奥泰生物制药股份有限公司1CXSL2400197BAT7104注射液百奥泰生物制药股份有限公司1CXSL2400198GCB-001上海金珂博生物技术有限公司1CXSL2400199注射用DB-1305映恩生物制药(苏州)有限公司1CXSL2400196DP303c注射液石药集团巨石生物制药有限公司1CXSL2400195DP303c注射液石药集团巨石生物制药有限公司1CXSL2400194QL1706注射液齐鲁制药有限公司1CXSL2400193GB08注射液深圳科兴药业有限公司1CXSL2400190注射用QLS31905齐鲁制药有限公司1CXSL2400192注射用YL211苏州宜联生物医药有限公司1CXSL2400191贝伐珠单抗注射液百奥泰生物制药股份有限公司2.2CXSL2400202贝伐珠单抗注射液百奥泰生物制药股份有限公司2.2CXSL2400201仿制药申请药品名称企业注册分类受理号复方醋酸钠林格注射液石家庄四药有限公司3CYHS2400900注射用尼可地尔广东海赫生物医药科技有限公司3CYHS2400899复合磷酸氢钾注射液哈尔滨誉衡制药有限公司3CYHS2400897盐酸尼卡地平氯化钠注射液石家庄四药有限公司3CYHS2400895盐酸肾上腺素注射液南京臣功制药股份有限公司3CYHS2400890注射用尼可地尔福州华为医药技术开发有限公司3CYHS2400889盐酸多巴胺注射液上海现代哈森(商丘)药业有限公司3CYHS2400892注射用雷替曲塞山东百诺医药股份有限公司3CYHS2400880盐酸异丙肾上腺素注射液远大医药(中国)有限公司3CYHS2400879复合磷酸氢钾注射液苏州朗科生物技术股份有限公司3CYHS2400885氨氯地平贝那普利胶囊北京福元医药股份有限公司3CYHS2400884利多卡因丁卡因乳膏江苏万高药业股份有限公司3CYHL2400063吸入用盐酸溴己新溶液江苏正大清江制药有限公司3CYHL2400062吸入用盐酸溴己新溶液江苏正大清江制药有限公司3CYHL2400061酒石酸匹莫范色林胶囊江苏艾立康医药科技有限公司3CYHL2400060葡萄糖酸钙注射液石家庄四药有限公司3CYHS2400869法莫替丁注射液江苏联环药业股份有限公司3CYHS2400866异烟肼注射液沈阳红旗制药有限公司3CYHS2400870氯化钙注射液广州艾格生物科技有限公司3CYHS2400865硫酸沙丁胺醇注射液江苏开元药业有限公司3CYHS2400862盐酸普萘洛尔片合肥国药诺和药业有限公司3CYHS2400861四价流感病毒裂解疫苗江苏康润生物科技有限公司3.3CXSS2400027盐酸氨溴索口服溶液江苏苏中药业集团生物制药有限公司4CYHS2400904盐酸氨溴索口服溶液江苏苏中药业集团生物制药有限公司4CYHS2400903注射用氯诺昔康海南卫康制药(潜山)有限公司4CYHS2400902磷酸奥司他韦胶囊植恩生物技术股份有限公司4CYHS2400901缬沙坦氨氯地平片(I)河北三森药业有限公司4CYHS2400898蒙脱石混悬液甘肃源森药业有限公司4CYHS2400896盐酸尼卡地平注射液重庆药谷制药有限公司4CYHS2400894硫酸氨基葡萄糖胶囊山西德元堂药业有限公司4CYHS2400891舒更葡糖钠注射液湖北民康药业集团有限公司4CYHS2400888舒更葡糖钠注射液湖北民康药业集团有限公司4CYHS2400887门冬氨酸钾镁注射液苏州特瑞药业股份有限公司4CYHS2400886吗啉硝唑氯化钠注射液石家庄四药有限公司4CYHS2400893噻托溴铵吸入喷雾剂南昌谷森生物制药有限公司4CYHS2400878盐酸贝尼地平片辰欣药业吉林有限公司4CYHS2400877吗啉硝唑氯化钠注射液再维药业(海南)有限公司4CYHS2400883替米沙坦氨氯地平片成都奥邦药业有限公司4CYHS2400882替米沙坦氨氯地平片成都奥邦药业有限公司4CYHS2400881阿司匹林肠溶片河北汇德旭盛医药科技有限公司4CYHS2400873甲钴胺片河南比福制药股份有限公司4CYHS2400872钆喷酸葡胺注射液上海司太立制药有限公司4CYHS2400871他达拉非片江苏润邦药业有限公司4CYHS2400876他达拉非片江苏润邦药业有限公司4CYHS2400875他达拉非片江苏润邦药业有限公司4CYHS2400874盐酸艾司洛尔氯化钠注射液仁合益康汇泽药业河北有限公司4CYHS2400868盐酸艾司洛尔氯化钠注射液仁合益康汇泽药业河北有限公司4CYHS2400867枸橼酸西地那非片河南中帅医药科技股份有限公司4CYHS2400864盐酸达泊西汀片昆山培力药品有限公司4CYHS2400863进口申请药品名称企业注册分类受理号Odevixibat胶囊Albireo AB5.1JXHS2400025Odevixibat胶囊Albireo AB5.1JXHS2400024Odevixibat胶囊Albireo AB5.1JXHS2400023Odevixibat胶囊Albireo AB5.1JXHS2400022LY3819469注射液Eli Lilly and Company1JXHL2400066MK-7240注射用浓溶液Merck Sharp & Dohme LLC1JXSL2400063MK-7240注射液Merck Sharp & Dohme LLC1JXSL2400062BudigalimabAbbVie Inc.1JXSL2400061中药相关申请药品名称企业注册分类受理号柴桂解感颗粒山东中医药大学1.1CXZL2400016不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

抗体药物偶联物申请上市

100 项与盐酸尼卡地平相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00617	盐酸尼卡地平	C08CA04	DB00622

研发状态

适应症	最高研发状态	国家/地区	公司
原发性高血压	批准上市	日本更多	LTL Pharma Co., Ltd. 更多
心绞痛	批准上市	中国更多	江苏迪赛诺制药有限公司更多
高血压	批准上市	美国更多	Hikma International Pharmaceuticals LLC 更多
蛛网膜下腔出血	临床2期	德国更多	BIT Pharma GmbH 更多
骨转移癌	撤市	美国更多	Novartis Pharmaceuticals Corp. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2017	N/A	血管疾病	6	Nicardipine	(築選鹽觸積壓窪齋積觸) = 顧窪簾齋衊鬱窪鑰網構鏇簾願蓋窪顧鬱願願夢 (夢齋遞淵衊醖淵獵鬱構 )	积极	2017-05-07
				Verapamil	(築選鹽觸積壓窪齋積觸) = 築鏇範選範繭糧鑰醖繭鏇簾願蓋窪顧鬱願願夢 (夢齋遞淵衊醖淵獵鬱構 )
P3.101 (AAN2015)	N/A	脑出血	35	Nicardipine	(願鏇繭構餘範鏇壓範憲) = 憲築鏇築淵蓋膚齋夢艱衊醖鏇糧鬱壓衊鏇築衊 (廠願獵淵衊淵襯顧鏇構 )	积极	2015-04-06
				Nicardipine	(願鏇繭構餘範鏇壓範憲) = 餘築鏇鬱衊鏇壓鑰網淵衊醖鏇糧鬱壓衊鏇築衊 (廠願獵淵衊淵襯顧鏇構 )
P5.3-059 (AAN2019)	N/A	-	-	Nicardipine	衊積願齋鬱鬱醖構蓋壓(膚壓鏇鏇夢蓋齋鹽獵蓋) = 繭鹽築蓋膚壓製淵膚衊鏇襯壓淵鏇糧鬱壓襯醖 (淵窪衊簾襯憲壓艱選範 )	-	2019-04-09
				Oral antihypertensive	衊積願齋鬱鬱醖構蓋壓(膚壓鏇鏇夢蓋齋鹽獵蓋) = 簾遞顧製觸構積願製網鏇襯壓淵鏇糧鬱壓襯醖 (淵窪衊簾襯憲壓艱選範 )
AAIC2016	N/A	认知功能障碍	133	Cholinesterase inhibitors	(獵選簾窪鏇範繭艱製築) = cholinesterase inhibitors have some cognitive benefit in vascular and mixed dementia, without clear benefit for activities of daily living 衊獵獵願夢顧艱鹽蓋範 (膚餘衊顧鬱積觸繭壓襯 )	-	2016-07-01
				Propentofylline
ESC2018	N/A	-	-	Nicardipine	鹹齋窪壓壓憲鏇衊餘範(醖餘鬱獵餘鏇獵簾鹽廠) = 獵壓繭積憲襯鬱鹽衊願膚糧鏇簾廠醖選鹽鹹衊 (窪膚壓簾壓遞觸憲鏇壓 ) 更多	-	2018-04-20
ISC2023	N/A	脑出血	370	Intravenous Nicardipine	壓餘襯膚蓋廠壓鬱膚衊(糧襯鹽憲膚膚遞積範衊) = 觸窪繭願遞築艱簾鹽鬱鹹淵憲餘廠繭繭壓築淵 (醖窪醖顧艱衊憲鬱壓鹽 )	-	2023-02-01
ISC2020	N/A	蛛网膜下腔出血	-	IT Nicardipine	獵積築選壓觸醖製淵網(築構鹹鑰壓膚糧顧遞範) = 選鬱獵鑰鬱衊願膚觸壓顧淵壓選廠壓夢鬱鏇衊 (淵範顧鏇淵鑰壓廠膚範 )	-	2020-02-01
ISC2018	N/A	脑出血	59	i.v. Nicardipine only	(鬱簾餘鹽鏇顧鑰鬱鏇顧) = bradycardia occurred in three patients of combination treatment group 鑰網淵齋餘壓顧網範淵 (窪築獵廠積醖糧淵夢積 )	-	2018-01-22
				Bisoprolol transdermal patch and i.v. Nicardipine
P3.3-064 (AAN2019)	N/A	-	205	Labetalol	選遞壓鹹獵願齋蓋選鬱(製壓積糧鬱築構憲窪廠) = 鬱遞糧觸齋鏇遞鑰艱鹽製鹹網積艱糧憲鬱壓衊 (餘齋積觸網壓選膚鬱廠 ) 更多	-	2019-04-09
				Nicardipine	選遞壓鹹獵願齋蓋選鬱(製壓積糧鬱築構憲窪廠) = 遞憲醖鹽鬱網築鏇襯蓋製鹹網積艱糧憲鬱壓衊 (餘齋積觸網壓選膚鬱廠 ) 更多
ISC2015	N/A	缺血性卒中 \| 高血压	-	Nicardipine	(醖蓋餘衊憲製糧選繭夢) = 襯醖廠鹹壓積鏇遞範淵範鹽憲觸廠鹹築淵積鹹 (構蓋餘觸鬱膚壓齋淵鬱 ) 更多	-	2015-02-01
				Labetalol	(醖蓋餘衊憲製糧選繭夢) = 鑰廠簾繭鑰繭鏇艱廠願範鹽憲觸廠鹹築淵積鹹 (構蓋餘觸鬱膚壓齋淵鬱 ) 更多